Search
Displaying all 9 results
Ustekinumab
go.drugbank.com/drugs/DB05679
ApprovedInvestigational
Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that binds the shared p40 subunit of interleukin (IL)-12 and IL-23. It is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Ustekinumab was first authorized in the European Union on 16 January 2009. T...
Moderate, active Crohn´s Disease
go.drugbank.com/conditions/DBCOND0123592Severe, active Crohn´s Disease
go.drugbank.com/conditions/DBCOND0123591Moderate, active Ulcerative colitis
go.drugbank.com/conditions/DBCOND0023313Severe, active Ulcerative colitis
go.drugbank.com/conditions/DBCOND0023312Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigational[A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment
Moderate Plaque psoriasis
go.drugbank.com/conditions/DBCOND0020390Drugs: Bimekizumab · Brodalumab · Clobetasol propionate · Deucravacitinib · Etanercept · Guselkumab +3 moreSevere Plaque psoriasis
go.drugbank.com/conditions/DBCOND0025583Drugs: Bimekizumab · Brodalumab · Clobetasol propionate · Deucravacitinib · Etanercept · Guselkumab +3 moreActive Psoriatic arthritis
go.drugbank.com/conditions/DBCOND0020384Drugs: Apremilast · Bimekizumab · Certolizumab pegol · Deucravacitinib · Golimumab · Guselkumab +5 more